India, Sept. 3 -- Polyrizon Ltd. (PLRZ), a development-stage biotechnology company, on Thursday announced definitive agreements with a single institutional investor for a registered direct offering and concurrent private placement, which are expected to generate aggregate gross proceeds of approximately $4 million.
Under the offerings, Polyrizon agreed to sell 333,333 units or pre-funded units at a combined offering price of $12 per unit. Each unit consists of one ordinary share, or one pre-funded warrant in lieu of an ordinary share, and one common warrant.
The registered direct offering includes 232,500 ordinary shares and 30,000 pre-funded warrants, while the concurrent private placement includes 70,833 PIPE pre-funded warrants and 333...